Syngene Reports 11% Rise in Q1 FY26 Operating Revenue

Syngene International Limited has announced results for the first quarter of FY26.

Quarterly Financial Highlights (All numbers are in Indian Rupees in Cr except margins)

*Excludes exceptional item of Rs. 21 crores (net of tax) in Q1 FY25 relating to final settlement from an insurance claim.

Commenting on the results, Peter Bains, Managing Director and CEO, Syngene International Limited, said, “We are pleased with the growth performance in the first quarter, which is aligned with our expectations. Continued conversion of pilot programs into longer-term contracts within our Research Services business was the main driver underpinning this momentum. In our Biologics manufacturing division, we have seen good progress with the start of operations at the Unit III facility in Bengaluru and in advancing preparations to commence operations at our Bayview facility in the U.S later this year. We continued to strengthen and expand our scientific platform capabilities, bringing online a state-of-the-art, dedicated peptide laboratory. While we remain mindful of ongoing macroeconomic factors, we maintain a confident outlook.”

Deepak Jain, Chief Financial Officer, Syngene International Limited, said, “We are pleased with the growth in revenue from operations of 11% year-on-year. Operating EBITDA margins came at around 24%, driven by both revenue growth and a focus on cost optimization. The current quarter’s PAT includes a tax benefit arising from transfer of gratuity funds to Employee Gratuity Trust. We continue to maintain a robust balance sheet enabling us to invest in technology and capabilities to strengthen our customer offerings. While keeping a close watch on market trends, we remain on course to deliver in line with our stated guidance for the year.”

Key Business Highlights:

·              Syngene successfully completed a USFDA Good Clinical Practices (GCP) inspection of its Human Pharmacology Unit with no observations. The Company’s Biologics facility at Biocon Park received an Establishment Inspection Report (EIR) with a favourable Voluntary Action Indicated (VAI) outcome. Additionally, the Company concluded over 20 client and regulatory audits in Q1 FY26, reinforcing its commitment to global quality and integrity standards.

·              Syngene inaugurated its new, state-of-the-art, dedicated peptide laboratory. Peptides are a fast- growing interventional modality that also complement Syngene’s existing capabilities in monoclonal antibodies, Antibody-Drug Conjugates, Oligonucleotides and PROTACs (proteolysis targeting chimeras).

·         Syngene was recognised by TIME magazine and Statista as one of the World’s Most Sustainable Companies in 2025. Syngene ranked #1 in India among companies in the pharma and biotech sectors and was ranked in the top 20 lifescience companies globally. Chosen from a pool of over 5,700 global organisations, this recognition underscores the Company’s steadfast commitment to environmental care and social responsibility.